151 related articles for article (PubMed ID: 2561738)
1. Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization.
Gewirtz DA; Ellis AL; Randolph JK; Yanovich S; Swerdlow PS; Povirk LF; Yalowich JC
Cancer Commun; 1989; 1(3):175-80. PubMed ID: 2561738
[TBL] [Abstract][Full Text] [Related]
2. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
Kerrigan D; Pommier Y; Kohn KW
NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
[TBL] [Abstract][Full Text] [Related]
3. Altered formation of DNA in human cells treated with inhibitors of DNA topoisomerase II (etoposide and teniposide).
Lönn U; Lönn S; Nylen U; Winblad G
Cancer Res; 1989 Nov; 49(22):6202-7. PubMed ID: 2553248
[TBL] [Abstract][Full Text] [Related]
4. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
[TBL] [Abstract][Full Text] [Related]
5. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
6. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier Y; Orr A; Kohn KW; Riou JF
Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
[TBL] [Abstract][Full Text] [Related]
9. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH
Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081
[TBL] [Abstract][Full Text] [Related]
10. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
11. Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines.
Dorr RT; Liddil JD; Gerner EW
Cancer Res; 1986 Aug; 46(8):3891-5. PubMed ID: 3015379
[TBL] [Abstract][Full Text] [Related]
12. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
13. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
Qiu J; Catapano CV; Fernandes DJ
Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.
Mattern MR; Mong SM; Bartus HF; Mirabelli CK; Crooke ST; Johnson RK
Cancer Res; 1987 Apr; 47(7):1793-8. PubMed ID: 3028614
[TBL] [Abstract][Full Text] [Related]
15. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.
Woynarowski JM; Sigmund RD; Beerman TA
Biochim Biophys Acta; 1988 May; 950(1):21-9. PubMed ID: 2833925
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW
Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540
[TBL] [Abstract][Full Text] [Related]
18. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
20. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.
Ross W; Rowe T; Glisson B; Yalowich J; Liu L
Cancer Res; 1984 Dec; 44(12 Pt 1):5857-60. PubMed ID: 6094001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]